Adam Kopp

Adam Kopp is a Senior Director of National Accounts at Rhythm Pharmaceuticals, where they lead national account initiatives for the company's rare disease product, Imcivree. With over twenty-five years of experience in market access, government accounts, and patient advocacy, Adam previously served as the Director of Government Accounts at Zogenix and Shire/Takeda, focusing on public payer strategy and policy development for rare diseases. Adam holds a Bachelor of Arts in Business/Corporate Communications from Kent State University and is dedicated to improving the lives of patients with rare and complex conditions.